Starpharma Holdings Limited (SPHRF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | -2.39 Million AUD | -175.99% |
| 2023 | 1.22 Million AUD | -35.86% |
| 2022 | 1.9 Million AUD | 89.28% |
| 2021 | 1 Million AUD | -80.42% |
| 2020 | 5.14 Million AUD | 267.36% |
| 2019 | 1.4 Million AUD | -63.27% |
| 2018 | 3.81 Million AUD | 27.41% |
| 2017 | 2.99 Million AUD | -21.78% |
| 2016 | 3.82 Million AUD | 375.75% |
| 2015 | 804 Thousand AUD | 194.51% |
| 2014 | 273 Thousand AUD | 1265.0% |
| 2013 | 20 Thousand AUD | -97.84% |
| 2012 | 925 Thousand AUD | -19.14% |
| 2011 | 1.14 Million AUD | -18.52% |
| 2010 | 1.4 Million AUD | -30.46% |
| 2009 | 2.01 Million AUD | 42.99% |
| 2008 | 1.41 Million AUD | 63.45% |
| 2007 | 863.85 Thousand AUD | 172670.8% |
| 2006 | 500.00 AUD | -99.98% |
| 2005 | 2.04 Million AUD | 47.37% |
| 2004 | 1.39 Million AUD | -6.35% |
| 2003 | 1.48 Million AUD | 285.99% |
| 2002 | 384.7 Thousand AUD | 0.0% |
| 2001 | - AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| 1998 | - AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | -1.74 Million AUD | -127.15% |
| 2024 Q1 | 1.28 Million AUD | 30.0% |
| 2024 Q2 | 6.42 Million AUD | 401.91% |
| 2024 FY | 7.09 Million AUD | 480.74% |
| 2024 Q4 | -1.74 Million AUD | 0.0% |
| 2023 Q3 | -1.8 Million AUD | -2521.01% |
| 2023 Q4 | 985 Thousand AUD | 154.47% |
| 2023 Q1 | -2.21 Million AUD | -320.84% |
| 2023 Q2 | -69 Thousand AUD | 96.88% |
| 2023 FY | 1.22 Million AUD | -35.86% |
| 2022 Q3 | -2.08 Million AUD | -641.69% |
| 2022 Q4 | 1 Million AUD | 148.09% |
| 2022 FY | 1.9 Million AUD | 89.28% |
| 2022 Q1 | -2.56 Million AUD | -417.41% |
| 2022 Q2 | 385 Thousand AUD | 115.03% |
| 2021 Q3 | -2.94 Million AUD | -1078.8% |
| 2021 Q1 | -3.24 Million AUD | -21516.67% |
| 2021 Q2 | -250 Thousand AUD | 92.29% |
| 2021 FY | 1 Million AUD | -80.42% |
| 2021 Q4 | 807 Thousand AUD | 127.38% |
| 2020 Q3 | -3.14 Million AUD | -174.03% |
| 2020 Q1 | -1.14 Million AUD | -197.74% |
| 2020 Q4 | -15 Thousand AUD | 99.52% |
| 2020 Q2 | 4.24 Million AUD | 470.11% |
| 2020 FY | 5.14 Million AUD | 267.36% |
| 2019 Q1 | 330.5 Thousand AUD | -82.2% |
| 2019 Q4 | 1.17 Million AUD | 29.87% |
| 2019 FY | 1.4 Million AUD | -63.27% |
| 2019 Q3 | 904 Thousand AUD | 173.52% |
| 2019 Q2 | 330.5 Thousand AUD | 0.0% |
| 2018 Q1 | 622 Thousand AUD | -59.85% |
| 2018 Q4 | 1.85 Million AUD | 0.0% |
| 2018 FY | 3.81 Million AUD | 27.41% |
| 2018 Q3 | 1.85 Million AUD | 198.47% |
| 2018 Q2 | 622 Thousand AUD | 0.0% |
| 2017 Q3 | 1.54 Million AUD | 464.3% |
| 2017 Q2 | 274.5 Thousand AUD | 0.0% |
| 2017 Q1 | 274.5 Thousand AUD | -29.16% |
| 2017 FY | 2.99 Million AUD | -21.78% |
| 2017 Q4 | 1.54 Million AUD | 0.0% |
| 2016 Q4 | 387.5 Thousand AUD | -13.21% |
| 2016 Q3 | 446.5 Thousand AUD | -76.12% |
| 2016 Q2 | 1.87 Million AUD | 0.0% |
| 2016 Q1 | 1.87 Million AUD | 287.97% |
| 2016 FY | 3.82 Million AUD | 375.75% |
| 2015 FY | 804 Thousand AUD | 194.51% |
| 2015 Q4 | 482 Thousand AUD | 0.0% |
| 2015 Q3 | 482 Thousand AUD | 31.51% |
| 2015 Q2 | 366.5 Thousand AUD | 0.0% |
| 2015 Q1 | 366.5 Thousand AUD | 37.78% |
| 2014 Q2 | 360.5 Thousand AUD | 0.0% |
| 2014 FY | 273 Thousand AUD | 1265.0% |
| 2014 Q4 | 266 Thousand AUD | 0.0% |
| 2014 Q3 | 266 Thousand AUD | -26.21% |
| 2014 Q1 | 360.5 Thousand AUD | -36.7% |
| 2013 Q3 | 569.5 Thousand AUD | -12.05% |
| 2013 Q4 | 569.5 Thousand AUD | 0.0% |
| 2013 FY | 20 Thousand AUD | -97.84% |
| 2013 Q1 | 647.5 Thousand AUD | 0.0% |
| 2013 Q2 | 647.5 Thousand AUD | 0.0% |
| 2012 FY | 925 Thousand AUD | -19.14% |
| 2011 FY | 1.14 Million AUD | -18.52% |
| 2010 FY | 1.4 Million AUD | -30.46% |
| 2009 FY | 2.01 Million AUD | 42.99% |
| 2008 FY | 1.41 Million AUD | 63.45% |
| 2007 FY | 863.85 Thousand AUD | 172670.8% |
| 2006 FY | 500.00 AUD | -99.98% |
| 2005 FY | 2.04 Million AUD | 47.37% |
| 2004 FY | 1.39 Million AUD | -6.35% |
| 2003 FY | 1.48 Million AUD | 285.99% |
| 2002 FY | 384.7 Thousand AUD | 0.0% |
| 2001 FY | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| 1998 FY | - AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 115.974% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 77340.49% |
| SQZ Biotechnologies Company | 9.79 Million USD | 124.464% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 120.468% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 102.012% |
| Mesoblast Limited | -35.16 Million USD | 93.187% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -6916.105% |
| Genus plc | 178.7 Million USD | 101.341% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 684.155% |
| Marizyme, Inc. | 457.7 Thousand USD | 623.485% |
| ContraFect Corporation | -154 Thousand USD | -1455.844% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -21681.818% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | -4692.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 3221.377% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 3745.326% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | -518.321% |
| MultiCell Technologies, Inc. | 49.32 USD | 4858169.749% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 105.951% |
| EV Biologics, Inc. | 48.9 Thousand USD | 4999.796% |
| Q BioMed Inc. | -8988.00 USD | -26557.766% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 108.48% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -15434.232% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 101.089% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 3522.857% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | -1828.355% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 3950.481% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -48284.491% |
| Arch Therapeutics, Inc. | -2439.00 USD | -98136.982% |
| IMV Inc. | -962.29 Thousand USD | -148.987% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 1805.338% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | -2357.058% |
| GB Sciences, Inc. | -624.00 USD | -383874.359% |
| Alpha Cognition Inc. | -86.02 Thousand USD | -2685.14% |
| HST Global, Inc. | - USD | Infinity% |
| CSL Limited | 7.56 Billion USD | 100.032% |
| Halberd Corporation | -208.00 USD | -1151823.077% |
| Enzolytics Inc. | 30.7 Thousand USD | 7902.527% |
| Resverlogix Corp. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 276.547% |
| SYBLEU INC | 11.69 Thousand USD | 20585.636% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 596.649% |
| argenx SE | 1.1 Billion USD | 100.216% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 90.712% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 488.089% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.585% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -26955.104% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 105.402% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | -109.886% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 342.515% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 124.93% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | -2757.518% |
| BioStem Technologies, Inc. | 15.42 Million USD | 115.533% |
| ONE Bio Corp. | 20.12 Million USD | 111.905% |
| Reve Technologies, Inc. | - USD | Infinity% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Agentix Corp. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -20145.036% |
| Cell Source, Inc. | - USD | Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | -4864.877% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 1457.046% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 1457.046% |
| NovAccess Global Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | -365.686% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | -280.234% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | -8162.069% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Qrons Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 632.394% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | -649.905% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 151.997% |
| Bioxytran, Inc. | -8285.00 USD | -28819.734% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | -542.359% |
| Neutra Corp. | 14.33 Thousand USD | 16814.336% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | -2821.951% |
| PureTech Health plc | -1.6 Million USD | -49.47% |
| Coeptis Therapeutics, Inc. | -1 Million USD | -139.304% |
| IXICO plc | 3.27 Million USD | 173.272% |
| IntelGenx Technologies Corp. | -694 Thousand USD | -245.245% |
| Gelesis Holdings, Inc. | -1.79 Million USD | -33.78% |
| CSL Limited | 7.7 Billion USD | 100.031% |
| Cellectis S.A. | 18 Thousand USD | 13411.111% |